FindTrial
Sign In

Understanding Antibody Development in Children Receiving Multiple Rituximab Doses for Nephrotic Syndrome

A Single Center Prospective Observational Study on Development of Anti-Rituximab Antibody (ARA) Following Treatment with Repeated Dose of Rituximab in Nephrotic Children - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/089208
Enrollment
20
Registered
2025-06-20
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N04- Nephrotic syndrome

Interventions

Intervention1: NIL: NIL

Sponsors

SCB Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children with nephrotic syndrome who have received more than or equal to 2 doses of Rituximab, the last dose of Rituximab being administered within last 1 month

Exclusion criteria

Exclusion criteria: Children with secondary nephrotic syndrome

Design outcomes

Primary

MeasureTime frame
Serum Anti-Rituximab Antibody levelTimepoint: 6 months, 12 months—

Secondary

MeasureTime frame
Number of RelapsesTimepoint: 6 months, 12 months—

Countries

India

Contacts

Public ContactDr Subal Kumar Pradhan

SCB MCH

drsubal@rediffmail.com9777860915

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026